Noteworthy, FTY720, which ameliorates brain injury through multiple mechanisms and is a strong candidate for stroke treatment (85), was the first Food and Drug Administration-approved nonselective S1P modulator used for the treatment of relapsing-remitting multiple sclerosis (86, 87). Here, MBTPS1 is linked to stroke disorder.